Sign In
Buy BCTX
$3.44
-0.190 (-5.23%)
At Close: Jul 31, 2026
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
07:30am, Wednesday, 30'th Apr 2025
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, inclu
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
04:05pm, Monday, 28'th Apr 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
08:00pm, Thursday, 24'th Apr 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher
10:11am, Thursday, 24'th Apr 2025
BriaCell Therapeutics Corp. BCTX confirmed on Thursday that it has sustained a complete resolution of the lung metastasis, first reported in February 2025, two months after the initial treatment in
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
07:30am, Thursday, 24'th Apr 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
07:30am, Wednesday, 23'rd Apr 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
07:30am, Tuesday, 22'nd Apr 2025
Over 75 patients enrolled in BriaCell's pivotal Phase 3 study of Bria-IMT ™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
07:30am, Wednesday, 16'th Apr 2025
PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
08:00am, Wednesday, 26'th Mar 2025
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
08:00am, Thursday, 20'th Mar 2025
PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
Biotechs on the Brink: 2 Stocks With Huge Potential
07:15am, Friday, 14'th Feb 2025
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug tr
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:56am, Tuesday, 11'th Feb 2025
After losing some value lately, a hammer chart pattern has been formed for BRIACELL THERAP (BCTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
06:15pm, Wednesday, 05'th Feb 2025
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage
BriaCell Therapeutics Announces Closing of Public Offering
04:05pm, Wednesday, 05'th Feb 2025
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
